NX Prenatal is developing the proprietary NeXosome® platform, which detects a new library of biomarkers for prenatal risk assessment as early as 10 weeks’ gestation providing physicians an opportunity to intervene for at-risk pregnancies to reduce the likelihood of a preterm birth.
Gail is a veteran women’s health diagnostics executive. In January 2013 Ms. Page founded Vineyard Investment Advisors to partner with entrepreneurs, businesses, and universities to transform their ideas into products and services. Prior to this, Gail served as the President, CEO and Director of Vermillion, Inc. from 2006 thru December 2012. Under her leadership, Vermillion developed and commercially launched the first FDA-cleared blood test to help diagnose ovarian cancer. Prior to this, Gail held executive leadership positions at Luminex, LabCorp, and Roche Biomedical.